Publications
Detailed Information
Prediction of Tumor Recurrence by (18)F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jeong Won | - |
dc.contributor.author | Paeng, Jin Chul | - |
dc.contributor.author | Kang, Keon Wook | - |
dc.contributor.author | Kwon, Hyun Woo | - |
dc.contributor.author | Chung, June-Key | - |
dc.contributor.author | Lee, Dong Soo | - |
dc.contributor.author | Lee, Myung Chul | - |
dc.contributor.author | Suh, Kyung-Suk | - |
dc.date.accessioned | 2012-06-29T02:18:17Z | - |
dc.date.available | 2012-06-29T02:18:17Z | - |
dc.date.issued | 2009-05-01 | - |
dc.identifier.citation | JOURNAL OF NUCLEAR MEDICINE; Vol.50; no.5; 682-687 | ko_KR |
dc.identifier.issn | 0161-5505 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77887 | - |
dc.description.abstract | Although several prognostic factors are used to predict recurrence and to select adequate candidates for liver transplantation for hepatocellular carcinoma (HCC), these prognostic factors have some clinical limitations. The purpose of this study was to evaluate (18)F-FDG PET as a prognostic factor and to optimize its ability to predict tumor recurrence in liver transplantation for HCC. Methods: The study included a total of 59 HCC patients (45 men and 15 women; mean age +/- SD, 56 +/- 8 y) who under-went (18)F-FDG PET and subsequent orthotopic liver transplantation. All patients were followed up for more than 1 y (mean, 29 +/- 17 mo), and recurrence of tumor was monitored. Three PET parameters-maximal standardized uptake value (SUV(max)), ratio of tumor SUV(max) to normal-liver SUV(max) (T(SUVmax)/L(SUVmax)), and ratio of tumor SUVmax to normal-liver mean SUV (T(SUVmax)/L(SUVmean))-were tested as prognostic factors and compared with conventional prognostic factors. Results: Among the 3 parameters tested, T(SUVmax)/L(SUVmax) was the most significant in the prediction of tumor recurrence, with a cutoff value of 1.15. In a multivariate analysis of various prognostic factors including T(SUVmax)/L(SUVmax), serum alpha-fetoprotein, T stage, size of tumor, and vascular invasion of tumor, T(SUVmax)/L(SUVmax) was the most significant, and only vascular invasion of tumor had additional significance. According to T(SUVmax)/L(SUVmax), the 1-y recurrence-free survival rate above the cutoff was markedly different from the rate below the cutoff (97% vs. 57%, P < 0.001). Conclusion: In this study, (18)F-FDG PET was an independent and significant predictor of tumor recurrence. In liver transplantation for HCC, (18)F-FDG PET can provide effective information on the prognosis for tumor recurrence and the selection of adequate candidates for liver transplantation. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SOC NUCLEAR MEDICINE INC | ko_KR |
dc.subject | FDG | ko_KR |
dc.subject | liver transplantation | ko_KR |
dc.subject | PET | ko_KR |
dc.subject | prognosis | ko_KR |
dc.subject | recurrence | ko_KR |
dc.title | Prediction of Tumor Recurrence by (18)F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이정원 | - |
dc.contributor.AlternativeAuthor | 팽진철 | - |
dc.contributor.AlternativeAuthor | 강건욱 | - |
dc.contributor.AlternativeAuthor | 권현우 | - |
dc.contributor.AlternativeAuthor | 서경석 | - |
dc.contributor.AlternativeAuthor | 정준기 | - |
dc.contributor.AlternativeAuthor | 이명철 | - |
dc.contributor.AlternativeAuthor | 이동수 | - |
dc.identifier.doi | 10.2967/jnumed.108.060574 | - |
dc.citation.journaltitle | JOURNAL OF NUCLEAR MEDICINE | - |
dc.description.citedreference | Chapman WC, 2008, ANN SURG, V248, P617, DOI 10.1097/SLA.0b013e31818a07d4 | - |
dc.description.citedreference | Yamamoto Y, 2008, J NUCL MED, V49, P1245, DOI 10.2967/jnumed.108.052639 | - |
dc.description.citedreference | Mazzaferro V, 2008, ANN SURG ONCOL, V15, P1001, DOI 10.1245/s10434-007-9559-5 | - |
dc.description.citedreference | Zimmerman MA, 2008, ARCH SURG-CHICAGO, V143, P182 | - |
dc.description.citedreference | Mocherla B, 2007, CLIN NUCL MED, V32, P947 | - |
dc.description.citedreference | Schwartz M, 2007, AM J TRANSPLANT, V7, P1875, DOI 10.1111/j.1600-6143.2007.01863.x | - |
dc.description.citedreference | Onaca N, 2007, LIVER TRANSPLANT, V13, P391, DOI 10.1002/lt.21095 | - |
dc.description.citedreference | Seo S, 2007, CLIN CANCER RES, V13, P427, DOI 10.1158/1078-0432.CCR-06-1357 | - |
dc.description.citedreference | Lo CM, 2007, BRIT J SURG, V94, P78, DOI 10.1002/bjs.5528 | - |
dc.description.citedreference | FOSTER R, 2007, CLIN LIVER DIS, V11, P417 | - |
dc.description.citedreference | Yang SH, 2006, LIVER TRANSPLANT, V12, P1655, DOI 10.1002/lt.20861 | - |
dc.description.citedreference | Taouli B, 2006, LIVER TRANSPLANT, V12, pS1, DOI 10.1002/lt.20935 | - |
dc.description.citedreference | Zavaglia C, 2005, AM J GASTROENTEROL, V100, P2708, DOI 10.1111/j.1572-0241.2005.00289.x | - |
dc.description.citedreference | Hwang S, 2005, LIVER TRANSPLANT, V11, P1265, DOI 10.1002/lt.20549 | - |
dc.description.citedreference | Sotiropoulos GC, 2005, TRANSPLANTATION, V79, P483, DOI 10.1097/01.TP.0000152801.82734.74 | - |
dc.description.citedreference | Sugiyama M, 2004, J GASTROENTEROL, V39, P961, DOI 10.1007/s00535-004-1427-5 | - |
dc.description.citedreference | Busuttil RW, 2004, ANN SURG, V240, P459 | - |
dc.description.citedreference | Del Gaudio M, 2004, HEPATO-GASTROENTEROL, V51, P510 | - |
dc.description.citedreference | Yoo HY, 2003, J CLIN ONCOL, V21, P4329, DOI 10.1200/JCO.2003.11.137 | - |
dc.description.citedreference | Graziadei IW, 2003, LIVER TRANSPLANT, V9, P557, DOI 10.1053/jlts.2003.50106 | - |
dc.description.citedreference | Ho CL, 2003, J NUCL MED, V44, P213 | - |
dc.description.citedreference | GREENE FL, 2002, AJCC CANC STAGING MA | - |
dc.description.citedreference | LEE WW, 2002, KOREAN J NUCL MED, V36, P368 | - |
dc.description.citedreference | Yao FY, 2001, HEPATOLOGY, V33, P1394 | - |
dc.description.citedreference | Shiomi S, 2001, AM J GASTROENTEROL, V96, P1877 | - |
dc.description.citedreference | Khan MA, 2000, J HEPATOL, V32, P792 | - |
dc.description.citedreference | Schlitt HJ, 1999, J CLIN ONCOL, V17, P324 | - |
dc.description.citedreference | Mazzaferro V, 1996, NEW ENGL J MED, V334, P693 | - |
dc.description.citedreference | TORIZUKA T, 1995, J NUCL MED, V36, P1811 | - |
dc.description.citedreference | PETRIDES AS, 1989, DIABETES METAB REV, V5, P691 | - |
dc.description.citedreference | EDMONDSON HA, 1954, CANCER, V7, P462 | - |
dc.description.tc | 19 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.